Actively Recruiting

Age: 18Years +
All Genders
ID06838611

ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation

Led by Medical University of Warsaw · Updated on 2025-02-20

300

Participants Needed

1

Research Sites

32 weeks

Total Duration

On this page

Sponsors

M

Medical University of Warsaw

Lead Sponsor

P

Poznan University of Medical Sciences

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to better understand patients with severe tricuspid regurgitation who are considered for transcatheter tricuspid valve interventions (TTVI). It seeks to describe patient profiles, reasons for disqualification from TTVI, and to evaluate both the immediate and long-term effectiveness and safety of these procedures. The study is observational and enrolls patients referred to specialized centers for evaluation and potential treatment of tricuspid valve disease. Participants may be qualified or disqualified for various interventions based on detailed heart imaging and clinical assessments. Those qualified might receive transcatheter tricuspid valve edge-to-edge repair (T-TEER) or other procedures like mitral valve repair, aortic valve implantation, or device implantations. Patients disqualified from TTVI receive medical therapy and follow-up. The enrollment lasts 36 months with each patient followed for 12 months or longer, including multiple clinical and imaging assessments at defined intervals. During the study, participants undergo clinical exams, echocardiography, laboratory tests, and assessments of heart function and aerobic capacity. Data on symptoms, heart failure status, and treatment outcomes are collected regularly, both in clinics and remotely if needed. The main outcomes include mortality and heart failure hospitalizations over 24 months, with additional measures of valve function, aerobic capacity, and quality of life. The study follows strict ethical guidelines and informed consent is obtained from all patients.

CONDITIONS

Brief Title

ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with tricuspid regurgitation
  • Qualified for transcatheter tricuspid valve intervention
  • Age 18 years or older
  • Able and willing to provide informed consent
Not Eligible

You will not qualify if you...

  • Qualified for surgical treatment of tricuspid regurgitation
  • Qualified for surgical treatment of concomitant left heart valve disease
  • Qualified for coronary artery bypass grafting due to multivessel coronary artery disease
  • Lack of patient's consent to enter the registry

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) during index hospitalization with clinical assessment and informed consent

Diagnostic Evaluation

Duration - Within index hospitalization

Participants undergo clinical assessments, transthoracic echocardiography (TTE), and other imaging to confirm severity of tricuspid regurgitation and to evaluate anatomy for possible interventions.

1 visit (in-person) during index hospitalization

Treatment

Duration - Up to index hospitalization and immediate post-procedure period

Participants either receive transcatheter edge-to-edge repair (T-TEER) or medical therapy depending on qualification. Those undergoing other non-tricuspid interventions will be reassessed before final treatment decision.

1 procedure visit (in-person) plus hospitalization period up to 7 days post-procedure

Post-treatment Follow-up

Duration - 12 months or longer

Participants are followed up with clinical, laboratory, and echocardiographic assessments to monitor treatment outcomes and heart failure status.

Outpatient visits at 1, 3, 6, and 12 months after treatment or medical therapy initiation, then annually

Trial Site Locations

Total: 1 location

1

First Department of Cardiology, Medical University of Warsaw

Warsaw, Masovian Voivodeship, Poland, 02-091

Actively Recruiting

Loading map...

Research Team

A

Adam Rdzanek, MD PhD

M

Mariusz Tomaniak, MD PhD Assoc. Prof.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Extensive Post-discharge Counselling and Phone-based Follow-...

Heart Failure

Actively Recruiting

1 location

Three-Dimensional Assessment of Right Ventricular Function i...

Heart Failure

Actively Recruiting

1 location

Myocardial Fibrosis in Heart Failure: A Pilot Study Using 68...

Myocardial Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here